A familial germline mutation in KIT associated with achalasia, mastocytosis and gastrointestinal stromal tumors shows response to kinase inhibitors

Marshall, 1990, Achalasia due to diffuse esophageal leiomyomatosis and inherited as an autosomal dominant disorder. Report of a family study, Gastroenterology, 98, 1358, 10.1016/0016-5085(90)90357-7 Beghini, 2001, Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa, Cancer, 92, 657, 10.1002/1097-0142(20010801)92:3<657::AID-CNCR1367>3.0.CO;2-D Hirota, 2002, Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene, Gastroenterology, 122, 1493, 10.1053/gast.2002.33024 Hirota, 2000, Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene, Am J Surg Pathol, 24, 326, 10.1097/00000478-200002000-00045 Isozaki, 2000, Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors, Am J Pathol, 157, 1581, 10.1016/S0002-9440(10)64795-5 Maeyama, 2001, Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene, Gastroenterology, 120, 210, 10.1053/gast.2001.20880 Nishida, 1998, Familial gastrointestinal stromal tumours with germline mutation of the KIT gene, Nat Genet, 19, 323, 10.1038/1209 O'Brien, 1999, Multiple familial gastrointestinal autonomic nerve tumors and small intestinal neuronal dysplasia, Am J Surg Pathol, 23, 198, 10.1097/00000478-199902000-00009 Robson, 2004, Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia, Clin Cancer Res, 10, 1250, 10.1158/1078-0432.CCR-03-0110 Zhang, 2006, A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy, Leuk Res, 30, 373, 10.1016/j.leukres.2005.08.015 Akin, 2004, A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib, Blood, 103, 3222, 10.1182/blood-2003-11-3816 Speight, 2013, Rare, germline mutation of KIT with imatinib-resistant multiple GI stromal tumors and mastocytosis, J Clin Oncol, 31, e245, 10.1200/JCO.2012.42.0133 Longley, 2001, Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy, Leuk Res, 25, 571, 10.1016/S0145-2126(01)00028-5 Sandberg, 2002, Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: alveolar soft part sarcoma, Cancer Genet Cytogenet, 136, 1, 10.1016/S0165-4608(02)00592-7 Metcalfe, 2002, Mastocytosis: molecular mechanisms and clinical disease heterogeneity, Leuk Res, 5 Kahler, 2007, Sensitive and reliable detection of Kit point mutation Asp 816 to Val in pathological material, Diagn Pathol, 2, 37, 10.1186/1746-1596-2-37 Schumacher, 2008, Detection of the c-kit D816V mutation in systemic mastocytosis by allele-specific PCR, J Clin Pathol, 61, 109, 10.1136/jcp.2007.047928 Tan, 2006, Sensitive detection of KIT D816V in patients with mastocytosis, Clin Chem, 52, 2250, 10.1373/clinchem.2006.068205 Verzijl, 2007, C-kit Asp-816-Val mutation analysis in patients with mastocytosis, Dermatology, 214, 15, 10.1159/000096907 de Melo Campos, 2014, Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412, Leuk Res, 38, 1245, 10.1016/j.leukres.2014.07.010 Chan, 2014, Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype, J Allergy Clin Immunol, 134, 178, 10.1016/j.jaci.2013.12.1090 Ke, 2016, Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis, Cell Biosci, 6, 55, 10.1186/s13578-016-0120-8 Hirota, 1998, Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors, Science, 279, 577, 10.1126/science.279.5350.577 Demetri, 2002, Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development, Hematol Oncol Clin North Am, 16, 1115, 10.1016/S0889-8588(02)00052-7 Huizinga, 1995, W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity, Nature, 373, 347, 10.1038/373347a0 Dematteo, 2009, Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial, Lancet, 373, 1097, 10.1016/S0140-6736(09)60500-6 Taylor, 2000, Kit signal transduction, Hematol Oncol Clin North Am, 14, 517, 10.1016/S0889-8588(05)70294-X Biasco, 2009, Gastrointestinal stromal tumors: report of an audit and review of the literature, Eur J Cancer Prev, 18, 106, 10.1097/CEJ.0b013e32830c8da8 Miettinen, 2005, Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up, Am J Surg Pathol, 29, 52, 10.1097/01.pas.0000146010.92933.de Bonadonna, 2009, Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings & increased serum tryptase levels, J Allergy Clin Immunol, 123, 680, 10.1016/j.jaci.2008.11.018 Genome Aggregation Database, Broad Institute. http://gnomad.broadinstitute.org/gene/ENSG00000157404. Accessed 16 November 2018. Samocha, 2014, A framework for the interpretation of de novo mutation in human disease, Nat Genet, 46, 944, 10.1038/ng.3050